FibroBiologics, LLC

Charleston, SC · Founded 2021 · CIK 0001958777 · Biotech · Public

M10, a novel synthetic peptide therapeutic for antifibrotic treatment

fibrobiologics.com →
Grants
$858K
3 awards
Sector median: 1
Raised
$11M
5 Form D · Sep 2026
0 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Preclinical Development of M10 as a Therapeutic Agent for Scleroderma$252,010
Federal grantDepartment of Health and Human Services · Phase I · Preclinical Development of a Novel Therapeutic Agent for Idiopathic Pulmonary Fibrosis$299,295
Federal grantDepartment of Health and Human Services · Phase I · Development of a Novel Therapeutic Agent for Skin Fibrosis$306,518
Private capital raised· 1 of 2 same dayForm D · SEC$1,500,000
Private capital raised· 2 of 2 same dayForm D · SEC$4,000,000
Private capital raisedForm D · SEC$1,725,001
Private capital raisedForm D · SEC$3,000,000
Private capital raisedForm D · SEC$500,001
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2224ArriVent Biopharma—$191M
2225MOBIUS SCIENTIFIC INC.——
2226PMV Pharmaceuticals—$74M
2227FibroBiologics, LLC—$11M
2228Diagonal Therapeutics——
2229Nimbus Therapeutics——
2230Inflection Medicine——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 7 related persons
  • Richard CilentoDirector
  • Stacy CoenDirector
  • Jason DavisExecutive Officer
  • Robert HoffmanDirector
  • Matthew LinkDirector
  • Victoria NiklasDirector
  • Pete O'HeeronDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.